Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike

Pseudotyped Luciferase GFP rSARS-CoV-2 Spike
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike

Principle: SARS-CoV-2 Spike pseudovirus infects 293T/ACE2 cells after incubation with the test antibody or serum.  The pseudovirus neutralization inhibition rate of the tested antibody or serum can be calculated based on the luciferase/GFP luminescence value.

Automation: No

Approvals: RUO

Capital equipment required: Yes

Description:

Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike is used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV2 spike protein. Pseudovirus display an antigenically-correct spike protein pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core.

Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike is capable of a single round of infection and carries a genome that expresses luciferase optical reporter gene upon infection. Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene.

Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so).

However, lentiviruses are capable of genomic integration, and pseudovirus is derived from biological materials so should be handled with caution within a BSL2 or enhanced BSL2 laboratory environment.


Key Points:
  • Used in SARS-CoV-2 Pseudovirus Neutralization Assay.
  • Safe in a BSL-2 environment.
  • High infectivity titer
  • Quantitative luciferase/GFP read-out
  • Quality-controlled production for use as a critical reagent

Areas:

    ClinicalPharmaceutical
Company contact details:

Creative Diagnostics view full details
NY 11967
United States

Website: Visit Website
Tel: 1-631-346-0027